Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who has given written consent.~* Patient between 18 and 64 years of age.~* Patient who has never received botulinum toxins~* Symptomatic patient in the context of bruxism in failure to the usual treatments (analgesic, physiotherapy, relaxation technique and maxillary retainer)~* Woman of childbearing age using an effective method of contraception~* Symptomatic patients in the context of bruxism, without a maxillary disocclusion retainer.~Exclusion Criteria:~* Protected Adult~* Patient not affiliated to the national health insurance system~* Pregnant or breastfeeding woman~* Refusal to take part in the study~* Neuromuscular diseases, including Myasthenia gravis, Myopathies, Amyotrophic Lateral Sclerosis. Lambert-Eaton Syndrome, patients with peripheral motor neuropathies, patients with underlying neurological disorders.~* Patients with a history of cardiovascular disease~* Patients with epilepsy or a previous seizure episode~* Neurogenic impairment of the face (including facial paralysis, polyradiculoneuritis)~* History of dysphagia or pulmonary aspiration~* Injection site infection (masseter and temporal)~* Hypersensitivity or allergy to botulinum toxin or any of its excipients.~* Treatment with aminoglycosides or anticholinesterase agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Symptomatic patients in the context of bruxism (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).